Sort
326,823 grants matching “clinical trial”
The Discovering Healthcare Innovations to Address Disparties in Stroke (DIADS) pr
$2,108,768Stephen Sidney · Kaiser Foundation Research Institute · U54 · FY2014 · NS
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit
$2,108,745Roy M Gulick · Weill Medical Coll Of Cornell Univ · UM1 · FY2016 · AI
Alzheimers Disease Patient Registry
$2,108,574Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2017 · AG
Alzheimers Disease Patient Registry
$2,108,574Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2016 · AG
Alzheimers Disease Patient Registry
$2,108,574Ronald C Petersen · Mayo Clinic Rochester · U01 · FY2018 · AG
Antibody Neutralization Mechanisms
$2,108,509Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Immunologic and Neurodevelopmental Consequences of Neonatal Anemia and Thrombocytopenia and their Treatments
$2,108,243Martha C Sola-Visner · Boston Children'S Hospital · P01 · FY2018 · HL
DEEP BRAIN STIMULATION FOR DEPRESSION USING DIRECTIONAL CURRENT STEERING AND INDIVIDUALIZED NETWORK TARGETING
$2,108,096Sameer Anil Sheth · Baylor College Of Medicine · UH3 · FY2019 · NS
The Darbepoetin Kindergarten Development Study
$2,108,079Carla M Bann · Research Triangle Institute · R01 · FY2025 · HL
Advancing the Development of a Humanized Anti-cocaine Monoclonal Antibody
$2,108,009Andrew B Norman · University Of Cincinnati · U01 · FY2015 · DA
Genes, environmental stressors, and the biobehavioral pathways to CVD
$2,107,419Redford B Williams · Duke University · P01 · FY2017 · HL
Alzheimer's dementia onset and progression in international cohorts (Amended)
$2,107,346Colin Masters · University Of Melbourne · R01 · FY2021 · AG
Shared Resource Group 1: Basic Oriented Facilities
$2,107,325Michael Barry Kastan · Duke University · P30 · FY2018 · CA
Shared Resource Group 1: Basic Oriented Facilities
$2,107,325Michael Barry Kastan · Duke University · P30 · FY2019 · CA
First-in-Human Clinical Development of a Novel Drug Candidate with a First-in-Class Mechanism for Smoking Cessation and Abstinence
$2,107,278Nurulain T Zaveri · Astraea Therapeutics, Llc · U01 · FY2022 · DA
The Role of Chemical Exposures in Alzheimer's Disease (AD) and its Trajectory
$2,107,225Rima F Kaddurah-Daouk · Duke University · U01 · FY2025 · AG
Administrative Core
$2,107,183Bradley F Boeve · Mayo Clinic Rochester · U19 · FY2025 · AG
University of Kentucky Markey Cancer Center - Cancer Center Support Grant
$2,107,000Bernard Mark Evers · University Of Kentucky · P30 · FY2017 · CA
University of Kentucky Markey Cancer Center - Cancer Center Support Grant
$2,107,000Bernard Mark Evers · University Of Kentucky · P30 · FY2016 · CA
CELLULAR AND MOLECULAR GEROSCIENCE CoBRE
$2,106,910William Edmund Sonntag · University Of Oklahoma Hlth Sciences Ctr · P20 · FY2023 · GM
BRAZILIAN AIDS PREVENTION TRIALS INTERNATIONAL NETWORK
$2,106,836University Of California Los Angeles · U01 · FY2003 · AI
Vanderbilt HIV Clinical Trials Unit (CTU)
$2,106,727David W Haas · Vanderbilt University Medical Center · UM1 · FY2023 · AI
Protective immunity following dengue virus natural infections and vaccination
$2,106,690Eva Harris · University Of California Berkeley · P01 · FY2015 · AI
Pro-inflammatory cytokine lowering anti-inflammatory drugs
$2,106,657Nigel H. Greig · National Institute On Aging · ZIA · FY2022 · AG
Stop Atherosclerosis in Native Diabetics study (SANDS)
$2,106,653Medstar Research Institute · U01 · FY2004 · HL